FindTrial
Sign In

Study for efficacy of 2 g azithromycin dose versus moxifloxacin 400 mg daily for 7 days in the treatment of urethral and rectal mycoplasma genitalium infection among Men who have sex with Men

Efficacy evaluation of azithromycin 2g dose and seven days doxycycline in the treatment of urethral and rectal mycoplasma genitalium infection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900024009
Enrollment
Unknown
Registered
2019-06-22
Start date
2019-07-15
Completion date
Unknown
Last updated
2019-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mycoplasma genitalium infection

Interventions

Group A:Extended azithromycin regimen: 1000 mg orally on the first day and 500 mg orally on the following 2 days.
Group B :Moxifloxacin regimen: 400 mg orally once a day for 7 days

Sponsors

Dermatology Hospital, Sourthern Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
20 Years to 49 Years

Inclusion criteria

Inclusion criteria: 1. MSM; 2. Positive test for mycoplasma genitalium using PCR performed on specimens of urethral or/and rectal swabs; 3. Aged between 20 and 49 years; 4. Adequate comprehension skills to give informed consent; 5. Able to attend 3 weeks post-completion therapy follow-up visits and provide urethral and rectal swabs; 6. Commitment to have not sexual behaviors for the next 4 weeks after initiating treatment.

Exclusion criteria

Exclusion criteria: 1. Self-report of antibiotic use in the last 4 weeks; 2. Unwillingness to participate in the study or provide informed consent; 3. Unwillingness to attend follow-up visits; 4. Known allergy to macrolides and/or tetracyclines; 5. Self-reported cardiovascular conditions and concomitant use of QT-prolonging drugs.

Design outcomes

Primary

MeasureTime frame
Mg DNA in urethral or/and rectal swabs;Side effect report rate;—

Countries

China

Contacts

Public ContactLi-Gang Yang

Dermatology Hospital, Sourthern Medical University

yanglg3@hotmail.com+86 13802983139

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026